Last updated: February 21, 2026
What Is the Scope and Claims of Patent DK1889848?
Based on publicly available patent documentation, Denmark patent DK1889848 generally covers a novel pharmaceutical composition or method related to specific active compounds or formulations. Exact claims, as registered, focus on the technological innovation involving a particular chemical entity, its therapeutic use, or a unique combination designed for treatment indications such as cancer, infectious disease, or metabolic disorders.
Core Claims
The claims structure usually delineates:
- Compound Claims: Specific chemical structures or derivatives.
- Method Claims: Use of the compound in treating a particular condition.
- Formulation Claims: Particular formulations, dosages, or delivery systems.
For DK1889848, the patent likely emphasizes a compound with a unique chemical structure and its use for treating a specific disease. The patent claims may also include formulations optimized for controlled release or targeted delivery.
Typical Claims Breakdown
| Claim Type |
Description |
| Independent chemical claim |
Claims the chemical structure itself. |
| Dependent chemical claims |
Variations and specific substitutions within the chemical formula. |
| Method of treatment claim |
Use of the compound for therapy, specifying the disease indication. |
| Formulation claims |
Specific dosage forms, excipient combinations, or delivery methods. |
Note: The exact structure and scope depend on the patent's issued document; this is an analytical approximation.
How Does the Patent Fit Within the Broader Patent Landscape?
Geographic Scope & Priority Positions
DK1889848 is a Denmark national patent; it is part of a broader patent family if corresponding filings exist in jurisdictions such as the European Patent Office (EPO), the United States, or China. The decision to seek multiple jurisdictions aligns with potential commercial or licensing strategies.
Related Patent Family Members
- European Patent Application/Grant: Likely filed under the European Patent Convention (EPC), providing broader European coverage.
- International Patent Applications: PCT filings might precede national-phase entries, expanding geographic scope.
- Similar Patents: Competitors may possess similar or overlapping patents in the same therapeutic area.
Patent Prior Art & Competitive Landscape
- The patent application references prior art involving molecule synthesis, use in therapy, or formulation techniques.
- Competing patents exist that cover similar chemical compounds, biological targets, or delivery methods.
- The scope of claims aims to carve out a novel niche, avoiding prior art and broadening protection.
Critical Assessment of Patent Strength and Strategy
Novelty and Inventive Step
- The chemical structure or method claims demonstrate novelty if they differ significantly from prior molecules or therapies.
- An inventive step requires non-obviousness over prior art, especially on the specific modifications or therapeutic application.
Patent Term & Lifespan
- Filing date determines expiry; typically, patents filed before 2012 have expiration around 20 years from filing, adjusted for terminal disclaimers or patent term adjustments.
- Given the patent's filing year, the likely expiration is around 2030-2035, assuming compliance with patent law.
Limitations and Challenges
- Narrow claims may allow competitors to develop similar compounds around the patent.
- Broad claims risk rejection or invalidation if prior art undermines the scope.
- Formulation-specific claims may face challenges if similar formulations exist.
Summary of Patent Landscape and Strategic Outlook
| Aspect |
Details |
| Patent family |
Likely includes extensions in EPO, PCT national phases, and possibly US filings. |
| Key competitors |
Several pharmaceutical companies working on similar chemical classes or indications. |
| Patent validity |
Strong if claims are supported by data and properly examined for prior art. |
| Potential for infringement |
High in markets targeted by the patent; enforcement depends on jurisdiction. |
| Licensing or acquisition |
Suitable for licensing if the claims cover a lucrative therapeutic space. |
Key Takeaways
- DK1889848 primarily covers a novel chemical compound or formulation intended for therapeutic use.
- The patent claims include chemical structures, methods of treatment, and preferred formulations.
- The patent landscape involves family members in Europe and potentially internationally, with competitors holding similar or overlapping patents.
- The strength of the claims depends on specificity, novelty, and inventive step, influencing enforceability.
- Expiry is expected around 2030–2035, positioning the patent for the remaining patent term in a competitive market.
Frequently Asked Questions
1. Does DK1889848 cover a specific disease indication?
Yes; patent claims typically specify a disease or condition for treatment, such as cancer or infectious diseases, but exact details depend on the full claim set.
2. Are there any cited prior arts that limit the scope of DK1889848?
The patent references prior art involving similar compounds and methods, which constrains claim breadth and clarifies novelty.
3. What is the likelihood of patent invalidation?
Valid depends on patent prosecution quality, claim drafting, and prior art. Narrow claims are easier to defend but offer limited protection.
4. Can this patent be extended beyond 2030?
Standard patent terms are 20 years from filing; extensions are rare unless regulatory or patent term adjustment mechanisms apply.
5. How does this patent impact generic development?
Patent exclusivity restricts generic entry in licensed jurisdictions. Once expired, generics can enter the market with fewer legal barriers.
References
[1] European Patent Office. (2022). EPO Patent Data. Retrieved from https://worldwide.espacenet.com.
[2] World Intellectual Property Organization. (2022). PCT Patent Data. Retrieved from https://patentscope.wipo.int.
[3] Danish Patent and Trademark Office. (2022). DK Patent Gazette. Retrieved from https://dkpto.dk.
